Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Fibroblast Growth Factor 20 Attenuates Colitis by Restoring Impaired Intestinal Epithelial Barrier Integrity and Modulating Macrophage Polarization via S100A9 in an NF-κB-Dependent Manner

D. Zhen, S. Wang, Z. Liu, Y. Xi, H. Du, N. Wang, X. Gao, Z. Lin, F. Wu

. 2025 ; 19 (6) : 101486. [pub] 20250228

Language English

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc25016423

BACKGROUND & AIMS: Exogenous recombinant fibroblast growth factor 20 (FGF20) protein has been proved to treat ulcerative colitis; however, its mechanism of action remains unclear. This study aimed to explore the role and mechanism of action of FGF20 in ulcerative colitis. METHODS: Data from patients with ulcerative colitis were analyzed using the Gene Expression Omnibus dataset. A murine colitis model was established by administering 2% dextran sodium sulfate. FGF20 knockout mice and Adenoassociated viruses (AAV)-FGF20-treated mice were used to elucidate the specific mechanisms. Proteomic analysis was conducted to identify differentially expressed genes. RESULTS: FGF20 levels were significantly elevated in the colonic tissues of subjects and mice with colitis. FGF20 deficiency exacerbated dextran sodium sulfate-induced colitis; in contrast, FGF20 replenishment alleviated colitis through 2 principal mechanisms: restoration of impaired intestinal epithelial barrier integrity, and inhibition of M1 macrophage polarization. Notably, S100A9 was identified as a pivotal downstream target of FGF20, which was further demonstrated by pharmacologic inhibition and overexpression experiments of S100A9 using paquinimod (a specific inhibitor of S100A9) and AAV-S100A9 in FGF20 knockout and AAV-FGF20 mice with colitis, respectively. Additionally, the nuclear factor-κB pathway was found to be involved in the process by which FGF20 regulates S100A9 to counteract colitis. CONCLUSIONS: These results suggest that FGF20 acts as a negative regulator of S100A9 and nuclear factor-κB, thereby inhibiting M1 macrophage polarization and restoring intestinal epithelial barrier integrity in mice with dextran sodium sulfate-induced colitis. FGF20 may serve as a potential therapeutic target for the treatment of ulcerative colitis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25016423
003      
CZ-PrNML
005      
20250731092905.0
007      
ta
008      
250708s2025 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcmgh.2025.101486 $2 doi
035    __
$a (PubMed)40024533
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a x
100    1_
$a Zhen, Dong $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
245    10
$a Fibroblast Growth Factor 20 Attenuates Colitis by Restoring Impaired Intestinal Epithelial Barrier Integrity and Modulating Macrophage Polarization via S100A9 in an NF-κB-Dependent Manner / $c D. Zhen, S. Wang, Z. Liu, Y. Xi, H. Du, N. Wang, X. Gao, Z. Lin, F. Wu
520    9_
$a BACKGROUND & AIMS: Exogenous recombinant fibroblast growth factor 20 (FGF20) protein has been proved to treat ulcerative colitis; however, its mechanism of action remains unclear. This study aimed to explore the role and mechanism of action of FGF20 in ulcerative colitis. METHODS: Data from patients with ulcerative colitis were analyzed using the Gene Expression Omnibus dataset. A murine colitis model was established by administering 2% dextran sodium sulfate. FGF20 knockout mice and Adenoassociated viruses (AAV)-FGF20-treated mice were used to elucidate the specific mechanisms. Proteomic analysis was conducted to identify differentially expressed genes. RESULTS: FGF20 levels were significantly elevated in the colonic tissues of subjects and mice with colitis. FGF20 deficiency exacerbated dextran sodium sulfate-induced colitis; in contrast, FGF20 replenishment alleviated colitis through 2 principal mechanisms: restoration of impaired intestinal epithelial barrier integrity, and inhibition of M1 macrophage polarization. Notably, S100A9 was identified as a pivotal downstream target of FGF20, which was further demonstrated by pharmacologic inhibition and overexpression experiments of S100A9 using paquinimod (a specific inhibitor of S100A9) and AAV-S100A9 in FGF20 knockout and AAV-FGF20 mice with colitis, respectively. Additionally, the nuclear factor-κB pathway was found to be involved in the process by which FGF20 regulates S100A9 to counteract colitis. CONCLUSIONS: These results suggest that FGF20 acts as a negative regulator of S100A9 and nuclear factor-κB, thereby inhibiting M1 macrophage polarization and restoring intestinal epithelial barrier integrity in mice with dextran sodium sulfate-induced colitis. FGF20 may serve as a potential therapeutic target for the treatment of ulcerative colitis.
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a lidé $7 D006801
650    12
$a NF-kappa B $x metabolismus $7 D016328
650    12
$a střevní sliznice $x patologie $x metabolismus $x imunologie $x účinky léků $7 D007413
650    12
$a makrofágy $x imunologie $x metabolismus $x účinky léků $7 D008264
650    _2
$a síran dextranu $x toxicita $7 D016264
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a myši knockoutované $7 D018345
650    12
$a kalgranulin B $x metabolismus $x genetika $7 D040502
650    12
$a ulcerózní kolitida $x patologie $x chemicky indukované $x imunologie $x metabolismus $x farmakoterapie $7 D003093
650    12
$a fibroblastové růstové faktory $x metabolismus $x genetika $x farmakologie $7 D005346
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a signální transdukce $7 D015398
650    12
$a kolitida $x chemicky indukované $7 D003092
655    _2
$a časopisecké články $7 D016428
700    1_
$a Wang, Songxue $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Liu, Zhen $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Xi, Yiyuan $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
700    1_
$a Du, Hanlin $u The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
700    1_
$a Wang, Ningrui $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Gao, Xiaotang $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
700    1_
$a Lin, Zhuofeng $u School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China; The Affiliated Songshan Lake Center Hospital, Guangdong Medical University, Dongguan, China. Electronic address: zlin@gdmu.edu.cn
700    1_
$a Wu, Fan $u The Affiliated Songshan Lake Center Hospital, Guangdong Medical University, Dongguan, China. Electronic address: zflwf@126.com
773    0_
$w MED00211331 $t Cellular and molecular gastroenterology and hepatology $x 2352-345X $g Roč. 19, č. 6 (2025), s. 101486
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40024533 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731092859 $b ABA008
999    __
$a ok $b bmc $g 2366930 $s 1253548
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 19 $c 6 $d 101486 $e 20250228 $i 2352-345X $m Cellular and molecular gastroenterology and hepatology $n Cell Mol Gastroenterol Hepatol $x MED00211331
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Archiving options